Lucentis 0.5 mg/0.05 ml Injection - Price, Uses, Dosage, Side Effects ( Ranibizumab)

Q: What are the indications for Lucentis?

Uses of Ranibizumab: - Diabetic eye disease - Wet age-related macular degeneration - Macular oedema due to retinal vein occlusion Wet ARMD, Central retinal vein occlusion, Diabetic macular edema Active or suspected ocular or periocular infection, active severe intraocular inflammation, signs of irreversible ischaemic visual function loss in patients w/ retinal vein occlusion.

Indications

Uses of Lucentis: - Diabetic eye disease - Wet age-related macular degeneration - Macular oedema due to retinal vein occlusion Wet ARMD, Central retinal vein occlusion, Diabetic macular edema Active or suspected ocular or periocular infection, active severe intraocular inflammation, signs of irreversible ischaemic visual function loss in patients w/ retinal vein occlusion.

Therapeutic Class

Drugs for Age-Related Macular Degeneration (AMD)

Pharmacology

Ranibizumab is a recombinant humanised IgG1 kappa monoclonal antibody fragment which binds to active forms of human vascular endothelial growth factor A (VEGF-A) and inhibits their biologic activity. Binding of ranibizumab to VEGF-A inhibits VEGF from binding to its receptors, thereby suppressing neovascularisation (angiogenesis), endothelial cell proliferation and vascular permeability.

Dosage and Administration

How to use Ranibizumab: Your doctor or nurse will give you this medicine. Kindly do not self administer. Adult Dose: Intravitreal Neovascular (wet) age-related macular degeneration Adult: 0.5 mg (0.05 mL of 10 mg/mL) mthly into the affected eye as a single dose. Continue treatment until visual acuity is stable for 3 consecutive mth. Doses are given at intervals of at least 1 mth. Macular oedema secondary to retinal vein occlusion Adult: 0.5 mg mthly into the affected eye as a single dose for 6 months. Doses are given at intervals of at least 1 mth. Diabetic Macular Edema, Diabetic Retinopathy with DME 0.3 mg (0.05 mL of 6 mg/mL) administer by intravitreal injection once a month (approximately every 28 days).

Interaction

May enhance the adverse/toxic effect of belimumab. Serious intraocular inflammation may occur when used adjunctively w/ verteporfin photodynamic therapy (PDT).

Contraindications

Active or suspected ocular or periocular infection, active severe intraocular inflammation, signs of irreversible ischaemic visual function loss in patients w/ retinal vein occlusion.

Side Effects

Common - Conjunctival hemorrhage - Eye pain - Eye inflammation - Increased intraocular pressure >10% Conjunctival hemorrhage (43-77%),Eye pain (17-37%),Vitreous floaters (3-32%),Incr IOP (8-24%),Vitreous detachment (7-22%),Eye irritation (4-19%),Intraocular inflammation (5-18%),Headache (2-15%),Upper resp tract infection (2-15%),Retinal disorder (13%),Blepharitis (3-13%),Retinal degeneration (1-11%) 1-10% Conjunctival hyperemia (9%),Posterior capsule opacification (8%),Injection site hemorrhage (5%),Vitreous hemorrhage (4%)

Pregnancy And Lactation

Pregnancy Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

Precautions And Warnings

Precaution: Patient w/ risk factors for retinal pigment epithelial tears, history of stroke or transient ischaemic attack, uncontrolled HTN, previous intravitreal inj, active systemic infections, proliferative diabetic retinopathy, diabetic macular oedema due to type 1 DM. Discontinue treatment if rhegmatogenous retinal detachment or stage 3 or 4 macular hole develops. Diabetic patients w/ glycosylated Hb over 12%. Lactation: Unknown if distributed in milk; use caution

Overdose Effects

Symptoms: Increased intraocular pressure, transient blindness, reduced visual acuity, corneal oedema, corneal pain, and eye pain. Management: Intraocular pressure should be monitored and treated by the attending physician, if necessary.

Storage Conditions

Store between 2-8° C. Protect from light.

Drug Classes